学位：博士学位
学历：研究生(博士)毕业
职称：教授
所在单位：湘雅基础医学院
学术荣誉： 曾获荣誉：
中南大学教授，博士生/博士后导师，现任中南大学基础医学院病理学系/湘雅医院病理科副主任、分子病理诊断中心主任。病理学国家级精品课程主讲教师、病理学国家级资源共享课程主讲教师及基础医学形态学国家级教学团队、卫计委临床重点专科骨干成员，副主编及参编《病理学》全国高等学校医学规划教材及配套教材15本，人民卫生出版社国家医学教育题库病理学学科副主编，获校级教学成果奖8项；参编专家共识2项。主持国家自然科学基金及省厅级项目10余项，作为子课题负责人参与湖南省重点研发计划项目一项，获湖南省医学学科C类项目一项（200万元）。近5年以通讯作者在PNAS、Cancer Research、Cell Discovery、Nucleic Acids Res、Signal Transduct Target Ther 、Molecular Cancer 、Advanced Science 等国际知名期刊发表论文61篇。获湖南医学科技奖一等奖一项、中华医学科技奖二等奖一项、中国抗癌协会科技奖二等奖一项。获湘雅医院医疗技术成果奖三等奖一项。湘雅医院十佳医师。
Desheng Xiao, Ph.D., professor, PhD candidate/post-doctoral supervisor, Deputy Director of Department of Pathology, Basic Medical School/Xiangya Hospital, Central South University, Director of Molecular Pathology Diagnosis Center. Main lecturer of the National Excellent Course of Pathology and the National Resource Sharing Course of Pathology, and a key member of the National Teaching Team of Basic Medical Morphology and the Key Clinical Specialty of the National Health and Family Planning Commission. Co-editor and contributor to 15 national medical planning textbooks and supplementary materials of "Pathology" published by People's Medical Publishing House, and deputy editor of the National Medical Education Question Bank of Pathology. Won 8 teaching achievement awards at the university level. Participated in the compilation of 2 expert consensus. Has presided over more than 10 projects funded by the National Natural Science Foundation and provincial and ministerial-level departments, and served as the sub-project leader of one key research and development project of Hunan Province, and obtained one C-class project of Hunan Medical Science and Technology (2 million yuan). In the past five years, 61 papers have been published as the corresponding author in international renowned journals such as PNAS, Cancer Research, Cell Discovery, Nucleic Acids Res, Signal Transduct Target Ther, Molecular Cancer, and Advanced Science. Won one first prize of Hunan Medical Science and Technology Award, one second prize of Chinese Medical Science and Technology Award, and one second prize of China Anti-Cancer Association Science and Technology Award. Won one third prize of Xiangya Hospital Medical Technology Achievement Award. Xiangya Hospital's top ten physicians.
Comparison of EML4-ALK fusion gene positive rate in different detection methods and samples of non–small cell lung cancer
点击次数：
影响因子：3.565
DOI码：10.7150/jca.36580
所属单位：中南大学
教研室：病理学系
发表刊物：J Cancer
关键字：EML4-ALK fusion gene; immunohistochemistry; reverse transcription-polymerase chain reaction; next-generation sequencing; non–small cell lung cancer
摘要：Objective: To evaluate differences of EML4-ALK positive rates in tissues samples between immunohistochemistry, reverse transcriptase polymerase chain reaction and the next-generation sequencing method. Besides, to compare the differences of EML4-ALK positive rates in blood samples and tissue samples by next-generation sequencing. The results provide a basis for the selection of a suitable EML4-ALK fusion gene detection method. Methods: Immunohistochemistry analysis of EML4-ALK in tumors was performed on samples from 2631 patients with non–small cell lung cancer. The mutation of EML4-ALK in the tissue samples of 399 patients with non–small cell lung cancer was detected by reverse transcription polymerase chain reaction. Next-generation sequencing was used to detect the mutation of EML4-ALK in 1505 non–small cell lung cancer patients, including 1208 tissue samples and 297 blood samples. Results: The positive incidence of EML4-ALK by immunohistochemistry was 7.11% (187/2631). Histologically, 9.51% (170/1787) of the samples were lung adenocarcinomas, and 2.01% (17/844) were squamous cell carcinomas. The positive rate of EML4-ALK was 8.52% (34/399) in 399 patients with non–small cell lung cancer, as detected by reverse transcription polymerase chain reaction; the mutation rate of adenocarcinoma was 11.62% (33/284), and the mutation rate of squamous cell carcinoma was 0.86% (1/115). In 1208 patients with non–small cell lung cancer with tissue samples, the positive rate of EML4-ALK was 4.88% (59/1208), as determined by next-generation sequencing, the mutation rate of adenocarcinoma was 5.84% (58/994), and the mutation rate of squamous cell carcinoma was 0.47% (1/214). The positive rate of EML4-ALK detected by reverse transcription polymerase chain reaction was higher than that detected by immunohistochemistry. Compared with the next-generation sequencing results, the positive rates of EML4-ALK detected by immunohistochemistry and reverse transcription polymerase chain reaction were higher, and the differences were significant (p<0.05). In blood samples from 297 patients with non–small cell lung cancer, the positive rate of EML4-ALK detected by next-generation sequencing was 3.70% (11/297), the mutation rate of adenocarcinoma was 3.82% (10/262), and the mutation rate of squamous cell carcinoma was 2.86% (1/35). The EML4-ALK positive rate of the tissue samples was thus higher than that of the blood biopsy samples. Conclusion: Among the three methods for detecting EML4-ALK, reverse transcription polymerase chain reaction has the highest positive rate, followed by immunohistochemistry, and next-generation sequencing has the lowest positive rate. The positive detection rate of EML4-ALK in tissue samples by next-generation sequencing was higher than that in blood samples.
合写作者：Can Lu, YuXuan Xiao, Wei Zhu, QiuYan He, Bin Xie, JianHua Zhou, YongGuang Tao, Shuang Liu
第一作者：Shan Lu
论文类型：期刊论文
通讯作者：DeSheng Xiao
学科门类：临床医学
卷号：11(6)
页面范围：1525-1531
是否译文：否
发表时间：2020-01-14
收录刊物：SCI
